Arthur Courroy

Cooley advised London-headquartered, NASDAQ-listed Silence Therapeutics, a global clinical-stage biotechnology company developing precision engineered medicines using its proprietary siRNA technology, on its agreement to be acquired by leading science and technology company Merck KGaA, Darmstadt, Germany, in an all-cash transaction with an equity value of approximately $1.3 billion, subject to the satisfaction of customary closing conditions. Under the terms of the agreement, Merck KGaA, Darmstadt, Germany, will acquire all outstanding ordinary shares of Silence. Upon completion of the transaction, Silence shareholders will receive $20.00 in cash per American Depositary Share (“ADS”), with each ADS representing three ordinary shares of Silence, a 130% premium to the Silence ADS closing price on Friday, October 16, 2026. The transaction, once completed, will add Divesiran ─ a potentially best-in-class, phase 3-ready siRNA investigational therapy, in development for phlebotomy-dependent polycythemia vera (PV) ─ to Merck KGaA, Darmstadt, Germany’s pipeline.

Cooley advised TechWolf BV on Agreement to be Acquired by SAP SE Cooley advised TechWolf BV, a leading AI work intelligence platform, on its agreement to be acquired by SAP SE, a global leader in enterprise applications and business AI. The deal is expected to close in Q4 2026, subject to customary closing conditions. Terms of the deal were not disclosed.

Cooley Advised Ambros Therapeutics on Merger With Werewolf Therapeutics, Concurrent $150 Million Private Financing

Cooley advised Ambros Therapeutics, a clinical-stage biotechnology company focused on the development of innovative and transformative medicines for diseases with high unmet medical need, on its definitive merger agreement with Werewolf Therapeutics for app. Upon completion of the merger, the combined company will operate as Ambros Therapeutics, headquartered in San Diego, California, and is expected to trade under the Nasdaq ticker symbol “AMBX”.

In connection with the transaction, Cooley also advised Ambros Therapeutics on a concurrent private financing of $150 million from a syndicate of leading healthcare-dedicated investors co-led by RA Capital Management and Janus Henderson Investors.

Cooley advised Scancell, a late-stage clinical biotechnology company, on its agreement to acquire Neuphoria Therapeutics, a clinical-stage biotechnology company dedicated to developing therapies that address the complex needs of individuals affected by neuropsychiatric disorders. Upon completion of the Transaction, the combined company plans to operate under the name Scancell and will apply to trade on Nasdaq under the symbol “SCLT”.